J

Johnson & Johnson

Makes prescription drugs and medical devices

Director, New Products Value and Evidence

Full-TimeUpdated on 10/23/2026
$164k - $282.9k+ Long-term incentive program
Senior
Master's, PhD
Hopewell Township, NJ, USA
HybridHybrid work in Titusville, NJ; travel up to 30%, mostly national with occasional international travel.
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • A minimum of a master's degree in Public Health, Health Services Research, Economics, Epidemiology, Pharmacy, Health Policy, or a related discipline is required.
  • A minimum of 7 or more years of relevant research experience is required.
  • Expertise in the healthcare industry, clinical knowledge or practice across multiple therapeutic areas, medical reimbursement, technical expertise in economic evaluations or patient-reported outcomes, including data analysis and statistics.
  • Demonstrated leadership, collaboration, influencing, and communication skills, including the ability to translate complex scientific and technical information into clear, decision-relevant insights for diverse audiences.
  • Experience communicating technical data internally and externally to non-technical audiences.
  • Independent high-level planning and execution of research strategies.
  • Solid experience conducting Real World Evidence studies applying health economics, patient-reported outcomes, retrospective data analyses, epidemiology, or health services research.
  • Firm understanding of the drug development process, including health economic inputs needed to support the value proposition.
  • Firm understanding of regulatory standards for approval and communication of data.
  • Strong understanding of the U.S. healthcare system, payer and access stakeholders, reimbursement models, health technology and value assessment, and the evolving policy environment that influences evidence expectations and patient access.
  • Firm understanding of the uses of evidence-based medicine and comparative effectiveness analyses for health policy decision-making.
  • Up to 30% travel is required, mostly national with occasional international travel.
Responsibilities
  • Ensure that real-world evidence and market access scientific requirements are identified early and integrated into U.S. development and business plans; develop evidence supporting differentiated value propositions reflecting payer and other access stakeholder needs; and lead NPV&E strategic planning to support development decisions, launch readiness, and sustained access.
  • Lead NPV&E strategy and execution, including formulating priority research questions; identifying analytical needs informing market access and development strategy; designing and conducting studies and market access analytics; managing publications; developing evidence and access communication materials; and partnering with V&ESE Field to enable effective, compliant scientific exchange with payer and other access stakeholders.
  • Ensure that NPV&E priorities are integrated into the Integrated Evidence Generation Plan (IEGP), aligned with business, payer, policy, and patient evidence needs, and executed with appropriate quality and timeliness.
  • Engage internal and external experts to refine evidence priorities and strengthen the scientific rigor and relevance of evidence-generation and dissemination plans.
  • Ensure compliance with regulatory, legal, and commercial regulations, such as Contract Pricing Committee and Copy Approval Committee requirements, when conducting research and disseminating scientific information.
  • Assess potential implications of the Inflation Reduction Act (IRA) and other evolving U.S. policy and reimbursement changes for pipeline assets, and translate those implications into early evidence priorities, development decisions, and lifecycle evidence needs, as appropriate.
  • Partner with cross-functional stakeholders to translate market access evidence needs into actionable scientific strategies and development recommendations for assigned products.
  • Initiate and manage selected research studies and related projects, including scope, timelines, resources, vendor oversight, and delivery of decision-relevant outputs.
  • Serve as the NPV&E subject-matter and functional expert for U.S.-focused health technology assessments, value assessments, and other external evidence reviews of assigned products, coordinating cross-functional responses and evidence strategies as appropriate.
  • Establish and maintain quality standards for the design, execution, interpretation, and publication of real-world evidence studies and for models and tools developed for business partners.
  • Develop the annual business plan budget, present it to appropriate levels of management for approval, and manage budgeted funds appropriately.
  • Ensure quality in internal and external communications, including publications, training support for RWVE studies, and models and tools developed to support the product.
Desired Qualifications
  • A doctorate or other advanced degree is preferred.
  • Experience developing and gaining management approval for value-based scientific strategies and tactics to meet both commercial and scientific objectives for a given product or therapeutic area.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.